EPAS1 and chromophobe renal cell carcinoma: ccRCC-specific EPAS1-binding sites were enriched for immune cell and white blood cell activation pathways and chRCC-specific EPAS1-binding sites were enriched for metabolic processes and fatty acid activation (Fig. 3E, F).